文献速递中枢神经肿瘤放疗姑息放疗与转移瘤

黑色素瘤脑转移患者生活质量的纵向轨迹:一项全脑放疗随机临床试验的二次分析

Longitudinal trajectory of quality of life for patients with melanoma brain metastases: A secondary analysis from a whole brain radiotherapy randomized clinical trial.
PubMed 文献 · Clin Transl Radiat Oncol · 2023-02-15

本研究基于多中心、前瞻性、开放标签、III期随机对照试验,描述1-3个黑色素瘤脑转移患者局部治疗后12个月的生活质量轨迹。合并观察组与全脑放疗组数据后,QLQ-C30和BN-20分别纳入139例和137例患者,9%-54%的患者在不同领域报告生活质量恶化。年龄≥65岁、女性、2-3个脑转移、未接受神经外科手术或接受辅助全脑放疗与较差的特定生活质量结局相关。

要点

  • 不同生活质量领域有9%-54%的患者报告恶化。
  • 年龄≥65岁与多个功能领域恶化及未来不确定性增加相关。
  • 女性、2-3个脑转移、未手术或辅助全脑放疗分别与特定较差结局相关。

核心结论

  • 诊断黑色素瘤脑转移后12个月内,年龄≥65岁、女性、有2-3个脑转移、转移灶未手术治疗或接受辅助全脑放疗的患者观察到较差的生活质量结局。

研究设计与样本

  • 本研究为多中心、前瞻性、开放标签、III期随机对照试验的二次分析,比较1-3个黑色素瘤脑转移局部治疗后辅助全脑放疗与观察的疗效。
  • 患者基线和每2个月完成欧洲癌症研究与治疗组织生活质量核心问卷(QLQ-C30)和脑肿瘤问卷(BN-20),持续12个月。
  • 采用增长混合模型识别有基线及至少一次随访评估患者的生活质量轨迹,并用多因素逻辑回归分析轨迹与人口学和临床因素的关联。
  • 合并观察组和全脑放疗组的生活质量数据后,QLQ-C30和BN-20轨迹分别基于139例和137例患者计算。

主要发现

  • 根据生活质量领域不同,9%-54%的患者报告生活质量恶化。
  • 年龄≥65岁与总体健康状况恶化(OR=2.88,95%CI=1.27-6.54)、躯体功能恶化(OR=3.49,95%CI=1.29-9.41)、角色功能恶化(OR=4.15,95%CI=1.77-9.71)、社会功能恶化(OR=4.42,95%CI=1.57-12.46)、认知功能恶化(OR=6.70,95%CI=1.93-23.29)、运动功能恶化(OR=4.95,95%CI=1.95-12.61)及未来不确定性增加(OR=0.20,95%CI=0.07-0.53)显著相关。
  • 女性与较差的躯体结局相关(OR=0.10,95%CI=0.02-0.41)。
  • 基线时未接受神经外科手术与较差的情绪结局相关(OR=0.09,95%CI=0.02-0.52)。
  • 有2-3个脑转移与较差的认知结局相关(OR=5.75,95%CI=1.76-18.85),接受辅助全脑放疗与较差的社会结局相关(OR=6.77,95%CI=2.00-22.99)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Brain metastases are common in patients with advanced melanoma. This study describes 12-month quality of life (QoL) trajectories following local management of 1-3 melanoma brain metastases. METHODS: This study assessed QoL data collected during a multi-center, prospective, open-label, phase III randomized controlled trial comparing the efficacy of adjuvant whole brain radiotherapy (WBRT) with observation after local treatment of 1-3 melanoma brain metastases. Patients completed the European Organization for Research and Treatment of Cancer Quality of Life Core (QLQ-C30) and Brain Tumour (BN-20) questionnaires at baseline and every 2 months, for 12 months.Using growth mixture modelling, QoL trajectories were identified for global health status, QLQ-C30 and BN-20 subscales for patients with baseline and at least one follow-up assessment. Multivariable logistic regression was used to examine associations between trajectories, demographic, and clinical factors. RESULTS: After combining QoL data from observation and WBRT arms, QLQ-C30 and BN-20 trajectories were calculated for 139 and 137 patients respectively. Depending on the QoL domain, 9-54 % of patients reported a deterioration in QoL. Older age (≥65 years) was significantly associated with deterioration in global health status (OR = 2.88, 95 %CI = 1.27-6.54), physical (OR = 3.49, 95 %CI = 1.29-9.41), role (OR = 4.15, 95 %CI = 1.77-9.71), social (OR = 4.42, 95 % CI = 1.57-12.46), cognitive (OR = 6.70, 95 % CI = 1.93-23.29) and motor functioning (OR = 4.95, 95 %CI = 1.95-12.61) and increased future uncertainty (OR = 0.20, 95 %CI = 0.07-0.53). Female sex (OR = 0.10, 95 %CI = 0.02-0.41), not having neurosurgery at baseline (OR = 0.09, 95 %CI = 0.02-0.52), 2-3 brain metastases (OR = 5.75, 95 %CI = 1.76-18.85) or receiving adjuvant WBRT (OR = 6.77, 95 %CI = 2.00-22.99) were associated with poorer physical, emotional, cognitive and social outcomes respectively. CONCLUSIONS: Poorer QoL outcomes in the first 12 months after diagnosis of melanoma brain metastases were observed in patients aged ≥ 65 years, females, having 2-3 brain metastases, non-surgical treatment of metastases or adjuvant WBRT.Clinical Trial Registration Number:Whole Brain Radiotherapy Trial (WBRTMel) was registered with the Australian Clinical Trials Registry (ACTRN12607000512426) and ClinicalTrials.gov (NCT01503827).Study Support:This project was funded by Cancer Australia PdCCRS (Grants No. 512358, 1009485, and 1084046) and the National Helath and Medical Research Coucil of Australia (NHMRC; Grant No. 1135285).ADT was supported by a Cancer Australia Priority-driven Collaborative Cancer Research Scheme. Project #1046923. RLM was supported by an NHMRC Fellowship #1194703 and a University of Sydney, Robinson Fellowship. JFT was supported by an NHMRC Program Grant #1093017.

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Bartula I, Tran AD, Nowak AK, et al. Longitudinal trajectory of quality of life for patients with melanoma brain metastases: A secondary analysis from a whole brain radiotherapy randomized clinical trial. Clin Transl Radiat Oncol. 2023. PMID: 37441544. doi:10.1016/j.ctro.2023.100597

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。